Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
Shares of US biotech Cytokinetics fell 6.6% to $57.96 by late morning yesterday, after it announced new data on its heart drug aficamten. 14 May 2024
Biotechnology
US rare diseases focused biotech Fulcrum Therapeutics has entered into a collaboration and license agreement with French pharma major Sanofi for the development and commercialization of losmapimod. 13 May 2024
Biotechnology
USA-based biotech Ajax Therapeutics today announced the completion of an oversubscribed $95 million Series C financing, led by Goldman Sachs with participation from new investors, including Eli Lilly. 13 May 2024
Biotechnology
Japanese pharma major Takeda and Massachusetts, USA-based firm AC Immune have inked a major new licensing deal. 13 May 2024
Biotechnology
Immuno-oncology company iTeos Therapeutics has lofty ambitions, claiming to be pioneering the discovery and development of a new generation of highly differentiated therapeutics in the field. 13 May 2024
Pharmaceutical
Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by involuntary movements, cognitive decline, and emotional disturbances.1 Recent global prevalence data cites 4.88 per 100,000 persons and an incidence of 0.48 cases per 100,000 person-years.2 13 May 2024
Biotechnology
Deal-making news last week included Italian family-owned Chiesi Farmaceutici announcing a licensing agreement with USA-based Gossamer Bio for the latter’s pulmonary hypertension candidate seralutinib worth up to $486 million. Among other news of note, the US Food and Drug Administration (FDA) plans to hold and advisory committee meeting on June 10 to review US Pharma major Eli Lilly’s Alzheimer’s disease candidate donanemab. Flagship Pioneering announced the launch of another start-up, Prologue Medicines, with $50 million financing to develop protein therapies. Gilead Science’s Kite unit and partner Arcellx updated on their development of investigational multiple myeloma drug anitocabtagene autoleucel. 12 May 2024
Biotechnology
Privately-held Californian company Maze Therapeutics has found a new partner for its investigational Pompe disease candidate in the form of Japan’s Shionogi. 11 May 2024
Pharmaceutical
Italian drugmaker Recordati has recorded net revenues of 608 million euros ($650 million) in the first quarter of 2024, up 10.2%. 10 May 2024
Pharmaceutical
French pharma major Sanofi says that, as part of its commitment to developing a diverse portfolio of best-in-class vaccines, it has entered into a co-exclusive licensing agreement with US biotech Novavax. 10 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze